NCT01924845终止3 期
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 22
- 主要终点
- Percent Predicted Maximum Inspiratory Pressure (MIP)
研究概览
简要总结
Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset Pompe disease who have been receiving treatment with recombinant human acid alpha-glucosidase (rhGAA) for 48 weeks or longer. Ambulatory patients who have mild to moderate respiratory impairment will switch directly to receive BMN 701 20 mg/kg by IV infusion every other week. All participants will receive active drug. No dose of existing therapy will be missed - experimental drug is started immediately.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any study-related procedures.
- •Diagnosed with late-onset Pompe disease based on 2 currently or previously documented GAA gene mutations, and endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay.
- •Has received prior treatment with commercial rhGAA as defined by ALL of the following:
- •has received treatment with commercial rhGAA for ≥ 48 weeks (but no more than 20% of the study population can have received treatment for ≥ 6 years).
- •has received > 80% of all scheduled treatments in the prior 48 weeks and ≥ 4 out of the prior 6 scheduled treatments.
- •has received and completed the last two infusions without a drug-related adverse event resulting in dose interruption.
- •has received last treatment of commercial rhGAA ≥ 10 and ≤ 31 days prior to anticipated initiation of treatment with BMN
- •≥ 18 years of age at the time of enrollment in the study.
- •Sexually active subjects must be willing to use two known effective methods of contraception while participating in the study and for at least 4 months following the last dose of BMN
- •Females of childbearing potential must have a negative pregnancy test at Screening and Baseline visits and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
- •Has ≥ 30% predicted upright FVC and < 80% predicted upright FVC.
- •Has ≤60% predicted MIP.
- •Is able to ambulate ≥75 meters and ≤500 meters on the 6MWT conducted during the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted with consistent use throughout the study).
- •Is willing and able to comply with all study procedures.
排除标准
- •Use of any investigational product or investigational medical device within 4 weeks prior to Screening, or requirement for any investigational agent other than BMN 701 prior to completion of at least the first 24 weeks of all scheduled study assessments.
- •Received any investigational medication for Pompe disease within the prior 12 months.
- •Has a diagnosis of diabetes and/or is currently being treated with or anticipated to require treatment with hypoglycemic agents during the course of the study.
- •Has been treated with any immunosuppressive medication other than glucocorticosteroids within the prior 12 months.
- •Requires noninvasive ventilatory support while awake and in the upright position.
- •Has previously been enrolled to this study.
- •Breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
- •Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the Investigator, might compromise subject safety, study treatment compliance and completion of the study, or the integrity of the data collected for the study.
- •Has known hypersensitivity to BMN 701 or its excipients.
研究组 & 干预措施
BMN 701 20 mg/kg
Experimental
BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
干预措施: BMN 701 (Drug)
结局指标
主要结局
Percent Predicted Maximum Inspiratory Pressure (MIP)
时间窗: Baseline, Week 24
Pulmonary function test: Percent Predicted Maximum Inspiratory Pressure
次要结局
- Percent Predicted Maximum Expiratory Pressure (MEP)(Baseline, Week 24)
- 6 Minute Walk Test (Meters)(Baseline, Week 24)
- Percent Predicted Upright Forced Vital Capacity (FVC)(Baseline, Week 24)
- Number of Participants With Non-Serious AEs(Baseline through Week 24 +4 weeks follow-up)
研究者
研究点 (22)
Loading locations...
相似试验
招募中
3 期
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic SyndromeNCT05935215Novartis Pharmaceuticals50
已完成
2 期
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseaseHematological DiseasesHemoglobinopathiesSickle Cell DiseaseNCT03745287Vertex Pharmaceuticals Incorporated63
已完成
3 期
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationColorectal Cancer (CRC)NCT05198934Amgen160
已完成
3 期
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)NCT01761266Eisai Limited954
已完成
3 期
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityBardet-Biedl SyndromePOMC Deficiency ObesityPCSK1 Deficiency ObesityLEPR Deficiency ObesityNCT04966741Rhythm Pharmaceuticals, Inc.12